

## **Curis to Present at Noble Financial Capital Markets 5th Annual Equity Conference**

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 11, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused developing next generation proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the Noble Financial Capital Markets 5th Annual Equity Conference, which is being held on August 18-19, 2008 in Las Vegas, Nevada. Curis' presentation will take place on Monday, August 18th at 6:30 p.m. Eastern Daylight Time (3:30 p.m. local time).

Michael P. Gray, Curis' Chief Financial and Chief Operating Officer, will provide a presentation that includes an overview of the status of GDC-0449, an orally-administered small molecule inhibitor of the Hedgehog pathway that is currently in Phase II clinical testing under collaboration with Genentech. Mr. Gray will also discuss CUDC-101 and Curis' other targeted cancer programs in addition to other corporate activities. There will also be a corresponding webcast of the presentation, which can be accessed by visiting:

<http://hosted.mediasite.com/hosted4/Viewer/?peid=f86a6ae0-8884-4625-bac0-0cdba6add131> (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will also be available for 30 days on the Investor Relations section of the Curis website at [www.curis.com](http://www.curis.com).

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its targeted cancer drug development platform, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at [www.curis.com](http://www.curis.com).

CONTACT: Curis, Inc.  
Michael P. Gray, 617-503-6632 [mgray@curis.com](mailto:mgray@curis.com)

SOURCE: Curis, Inc.

---

<https://investors.curis.com/Curis-to-Present-at-Noble-Financial-Capital-Markets-5th-Annual-Equity-Conference>